The European Commission’s approval of BioMarin’s novel gene therapy for severe hemophilia A has paved the way for ARUP’s AAV5 DetectCDx™ Kit to become the first ARUP-developed test used in Europe.
Ryan Metcalf, MD, CQA(ASQ), section chief of Transfusion Medicine at ARUP and University of Utah Health, at ARUP Blood Services, a collection site for an ARUP/University of Utah Health study to determine whether convalescent plasma is an effective treatment for COVID-19.
Based on data from 21,916 participants in 33 studies, the Association for the Advancement of Blood and Biotherapies (AABB) has issued guidelines for use of convalescent plasma in COVID-19 treatment.
In her lab at the University of Utah, Allison Carey, MD, PhD, is using a molecular barcoding approach she developed to identify the genes that allow some strains of Mycobacterium avium to establish chronic infections and resist treatment with antibiotics.
The National Institute of Allergy and Infectious Diseases has awarded Medical Director Allison Carey, MD, PhD, $1.5 million over five years to fund her groundbreaking research.
NanoSpot.ai’s agreement with the Greek company Opto enables the commercialization and distribution in Europe of NanoSpot.ai’s line of antibody tests, including the SARS-CoV-2 test pictured here.
NanoSpot.ai’s European commercialization agreement is the first for an antibody test originally developed through an ARUP/University of Utah/Techcyte partnership.
These images depict the distinct genetic profiles found in patients with pathogenic germline DDX41 variants and variants of unknown significance (VUSs).
New research published in Blood sheds light on diagnosis, disease characteristics, and prognoses for inherited hematologic malignancies associated with DDX41 germline variants.
Patricia Slev, PhD, section chief of Immunology at ARUP Laboratories, coauthored a newly published study that looked at COVID-19-related risks facing emergency department workers early in the pandemic.
A new study for which ARUP provided COVID-19 testing and expertise found that emergency department workers early in the pandemic faced the highest risk of infection from community spread.
ARUP’s new autonomous intelligent vehicle (AIV) helps its coworkers in the lab by transporting specimens to storage, freeing up staff to focus on other tasks. Here, a team member unloads samples delivered by the AIV.
ARUP’s latest autonomous intelligent vehicle (AIV) is on a mission to save time and trouble for its coworkers in the lab. As a new teammate, the AIV is a seamless and helpful fit.
The Summer 2022 edition of Magnify, now online, features a look at the challenges of autoimmune neurologic testing, our experts in this area, and recent awards, and catches up with a former fellow.
ARUP medical directors and scientists will share their research and expertise in areas like lab stewardship, biochemical genetics, and neonatal drug testing at AACC’s 2022 annual meeting in Chicago.
Scientist Michael T. Pyne shares ARUP’s challenges and process of developing a next generation sequencing (NGS) test for HIV-1 antiretroviral drug resistance.
ARUP experts say that the VALID Act, which would require FDA approval of all lab-developed tests, would add administrative and financial burdens to an already safe and effective validation process.
ARUP experts are to give six talks and poster presentations at the flagship annual meeting of the American Society for Microbiology (ASM) in Washington, D.C.